AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1464075 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 34
Study 2866062 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blocking drugs (atenolol, propranolol, pindolol)
Number of subjects: 17
Study 2866062 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (beta 1- and beta 2-blocker)
Number of subjects: 17
Study 2866062 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (atenolol, propranolol, pindolol)
Number of subjects: 17
Study 2866062 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol
Number of subjects: 17
Study 2866062 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 17
Study 31969201 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram combined with memantine
Number of subjects: 22
Study 31969201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30297313 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐μm plus 100‐μm PVA particles (group A)
Number of subjects: 120
Study 30297313 — intervention group
Group type: COMPARATOR
Intervention: 100‐μm PVA particles alone (group B)
Number of subjects: 120
Study 30297313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 25863804 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB (Drug-Eluting Balloon)
Number of subjects: 30
Study 25863804 — intervention group
Group type: COMPARATOR
Intervention: BMS (Bare-Metal Stent)
Number of subjects: 30
Study 25863804 — intervention group
Group type: EXPERIMENTAL
Intervention: pre-DEB
Number of subjects: 30
Study 25863804 — intervention group
Group type: EXPERIMENTAL
Intervention: post-DEB
Number of subjects: 30
Study 23771989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 138
Study 23771989 — intervention group
Group type: COMPARATOR
Intervention: Free-managed diet (FD)
Number of subjects: 138
Study 23771989 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (≥5%)
Number of subjects: 138
Study 23771989 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss categories (<5%, 5-10%, >10%)
Number of subjects: 138
Study 23631690 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement drop jump training
Number of subjects: 103
Study 23631690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce drop jump training
Number of subjects: 103
Study 23631690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 21111094 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic meal group (seven diagnosis-appropriate therapeutic meals a week)
Number of subjects: 321
Study 21111094 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy (MNT)
Number of subjects: 321
Study 21111094 — intervention group
Group type: EXPERIMENTAL
Intervention: MNT plus therapeutic meals
Number of subjects: 321
Study 21111094 — intervention group
Group type: COMPARATOR
Intervention: Literature control group
Number of subjects: 321
Study 18181808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential anticoagulation (citrate for the first 3.5 h, switching to 30‐min anticoagulation‐free hemodialysis)
Number of subjects: 52
Study 18181808 — intervention group
Group type: COMPARATOR
Intervention: Standard citrate anticoagulation
Number of subjects: 52
Study 15902989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chokeberry juice (150 mL daily, containing 23 mg/100 mL of anthocyanins)
Number of subjects: 0
Study 15902989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 12919306 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles and psychosocial variables in Graz group
Number of subjects: 424
Study 12919306 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles and psychosocial variables in Jerusalem group
Number of subjects: 424
Study 12919306 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial variables affecting psychological distress
Number of subjects: 424
Study 10048367 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography (ICG)
Number of subjects: 17
Study 10048367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 17
Study 10048367 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography (ICG) and Fluorescein angiography (FA)
Number of subjects: 17
Study 8948373 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine immunoglobulin concentrate (powder form) for 21 consecutive days
Number of subjects: 24
Study 8948373 — intervention group
Group type: COMPARATOR
Intervention: Bovine immunoglobulin concentrate (capsule form)
Number of subjects: 24
Study 8948373 — intervention group
Group type: COMPARATOR
Intervention: Patients without C. parvum (cohort 3)
Number of subjects: 24
Study 1661057 — intervention group
Group type: EXPERIMENTAL
Intervention: High titre varicella vaccine (5300 PFU)
Number of subjects: 100
Study 1661057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low titre varicella vaccine (2000 PFU)
Number of subjects: 100
Study 1661057 — intervention group
Group type: COMPARATOR
Intervention: Combined varicella and MMR vaccine (high titre)
Number of subjects: 100
Study 1661057 — intervention group
Group type: COMPARATOR
Intervention: Combined varicella and MMR vaccine (low titre)
Number of subjects: 100
Study 1661057 — intervention group
Group type: EXPERIMENTAL
Intervention: Single varicella vaccine (both titre levels)
Number of subjects: 100
Study 7213522 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (oral and i.v. dosing)
Number of subjects: 10
Study 7213522 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (i.v. dosing)
Number of subjects: 10
Study 7213522 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (oral dosing)
Number of subjects: 10
Study 31740021 — intervention group
Group type: EXPERIMENTAL
Intervention: D2BT <90 minutes
Number of subjects: 1550
Study 31740021 — intervention group
Group type: EXPERIMENTAL
Intervention: D2BT >90 minutes <24 hours
Number of subjects: 1550
Study 31740021 — intervention group
Group type: EXPERIMENTAL
Intervention: D2BT >24 hours
Number of subjects: 1550
Study 30535949 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12
Study 30535949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28146137 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal mesh repair (TVMR)
Number of subjects: 39
Study 28146137 — intervention group
Group type: COMPARATOR
Intervention: Stapled transanal rectal resection (STARR)
Number of subjects: 39
Study 25649214 — intervention group
Group type: EXPERIMENTAL
Intervention: AS replacement every 7 days
Number of subjects: 6554
Study 25649214 — intervention group
Group type: COMPARATOR
Intervention: AS replacement every 4 days (control)
Number of subjects: 6554
Study 23671213 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 61
Study 23671213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 61
Study 21895677 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of RBCs after 14 days of storage
Number of subjects: 25
Study 21895677 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of RBCs after 28 days of storage
Number of subjects: 25
Study 19440010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml lidocaine‐prilocaine cream perianally
Number of subjects: 80
Study 19440010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine‐prilocaine cream perianally and intrarectally
Number of subjects: 80
Study 19440010 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (control group)
Number of subjects: 80
Study 17045952 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron mouthrinse (10mL of 10mM ferrous sulphate solution) after immersion in cola drink for 5min, followed by brushing after 1min or 30min.
Number of subjects: 10
Study 17045952 — intervention group
Group type: COMPARATOR
Intervention: No treatment after immersion in cola drink.
Number of subjects: 10
Study 17045952 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice brushing after 1min or 30min post-immersion.
Number of subjects: 10
Study 15321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoglutamyl folic acid (323 nmol/d)
Number of subjects: 180
Study 15321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptaglutamyl folic acid (262 nmol/d)
Number of subjects: 180
Study 15321811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 11756369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) pills
Number of subjects: 100
Study 11756369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9649716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol
Number of subjects: 0
Study 9649716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate
Number of subjects: 0
Study 7855551 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 6.5 mg per kg body weight b.i.d. (children) or 300 mg t.i.d. (adults) for 10 days
Number of subjects: 239
Study 7855551 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin 12.5 mg per kg body weight b.i.d. for 10 days
Number of subjects: 239
Study 2526622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (2 micrograms or 0.1 ml) intradermal hepatitis B vaccine
Number of subjects: 32
Study 2526622 — intervention group
Group type: COMPARATOR
Intervention: Standard (20 micrograms or 1 ml) intramuscular hepatitis B vaccine
Number of subjects: 32
Study 856569 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg reproterol
Number of subjects: 81
Study 856569 — intervention group
Group type: COMPARATOR
Intervention: 20 mg orciprenaline
Number of subjects: 81
Study 31558100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dader Method for Pharmaceutical Care (PC)
Number of subjects: 131
Study 31558100 — intervention group
Group type: COMPARATOR
Intervention: Institution's usual care
Number of subjects: 131
Study 28601627 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg dexmedetomidine
Number of subjects: 78
Study 28601627 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 78
Study 26471380 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 100 mg/day
Number of subjects: 768
Study 26471380 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 200 mg/day
Number of subjects: 768
Study 26471380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 768
Study 24073548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination travoprost 0.004%/timolol 0.5%
Number of subjects: 60
Study 24073548 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination dorzolamide 2%/timolol 0.5%
Number of subjects: 60
Study 24073548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 21791117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single task gait training with cueing strategies to increase step length
Number of subjects: 60
Study 21791117 — intervention group
Group type: COMPARATOR
Intervention: Dual task gait training to improve step length while performing added tasks
Number of subjects: 60
Study 21791117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single task gait training
Number of subjects: 60
Study 21791117 — intervention group
Group type: COMPARATOR
Intervention: Dual task gait training
Number of subjects: 60
Study 19180530 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief self-administered psychological intervention
Number of subjects: 46
Study 19180530 — intervention group
Group type: COMPARATOR
Intervention: Deferred entry group (control)
Number of subjects: 46
Study 17988323 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel spatial particle during habituation
Number of subjects: 0
Study 17988323 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel word as a count noun
Number of subjects: 0
Study 17988323 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel count noun
Number of subjects: 0
Study 17988323 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel particle (possibly assisted by a familiar verb)
Number of subjects: 0
Study 15050908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact circuit intervention (12 min, three times a week) for 20 months
Number of subjects: 31
Study 15050908 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 maturity-matched boys)
Number of subjects: 31
Study 12383664 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-assisted PCI
Number of subjects: 988
Study 12383664 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 988
Study 9830258 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 22
Study 9830258 — intervention group
Group type: COMPARATOR
Intervention: typical antipsychotic medication
Number of subjects: 22
Study 7973751 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative and functional treatment with AIRCAST pneumatic leg braces, including a lower leg cast for 2 weeks followed by mobilization with protection from the brace.
Number of subjects: 29
Study 2689314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmo-Timelets (600 mg theophylline)
Number of subjects: 12
Study 2689314 — intervention group
Group type: COMPARATOR
Intervention: Theophylline controlled-release tablet (600 mg theophylline)
Number of subjects: 12
Study 30366361 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted circulating vitamin K₁ levels (per 1 nmol/L increase)
Number of subjects: 34217
Study 26822714 — intervention group
Group type: EXPERIMENTAL
Intervention: UC‐II (40 mg daily)
Number of subjects: 191
Study 26822714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 26822714 — intervention group
Group type: COMPARATOR
Intervention: GC (1500 mg G & 1200 mg C)
Number of subjects: 191
Study 23681502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 'whole muscle' training (resistance + aerobic) and inspiratory muscle training (IMT)
Number of subjects: 20
Study 23681502 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 20
Study 23837717 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation (TSF) sessions
Number of subjects: 32
Study 20542554 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg per day)
Number of subjects: 65
Study 20542554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 19025919 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression with basiliximab and cyclosporine without prednisone (NoSt group)
Number of subjects: 89
Study 19025919 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppression with basiliximab and cyclosporine with prednisone (St group)
Number of subjects: 89
Study 16085238 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive combined modality treatment arm for patients with poor prognosis
Number of subjects: 738
Study 16085238 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen only
Number of subjects: 738
Study 16085238 — intervention group
Group type: COMPARATOR
Intervention: Surgery with radiotherapy to the axilla
Number of subjects: 738
Study 16085238 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 738
Study 14989462 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa for 6 months
Number of subjects: 15
Study 14989462 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 15
Study 10579146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus administered after a high-fat meal (15 mg single dose)
Number of subjects: 0
Study 10579146 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus administered while fasting (15 mg single dose)
Number of subjects: 0
Study 9103685 — intervention group
Group type: EXPERIMENTAL
Intervention: Millet porridge
Number of subjects: 15
Study 9103685 — intervention group
Group type: EXPERIMENTAL
Intervention: White rice
Number of subjects: 15
Study 9103685 — intervention group
Group type: EXPERIMENTAL
Intervention: English potatoes
Number of subjects: 15
Study 9103685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereals (including millet and maize meal)
Number of subjects: 15
Study 9103685 — intervention group
Group type: EXPERIMENTAL
Intervention: English potatoes, maize meal, millet, and cassava
Number of subjects: 15
Study 1899644 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous release transdermal nitroglycerin (group 1)
Number of subjects: 30
Study 1899644 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous release transdermal nitroglycerin (group 2)
Number of subjects: 30
Study 6179617 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracyclines (daunomycin and Adriamycin)
Number of subjects: 306
Study 6179617 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin during induction of remission and maintenance therapy
Number of subjects: 306
Study 31476539 — intervention group
Group type: COMPARATOR
Intervention: Buccal‐based triangular flap (Group 1)
Number of subjects: 30
Study 31476539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual‐based triangular flap (Group 2)
Number of subjects: 30
Study 31476539 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 31522612 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-legalisation message
Number of subjects: 0
Study 31522612 — intervention group
Group type: COMPARATOR
Intervention: Pro-legalisation message
Number of subjects: 0
Study 31522612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-NC participants
Number of subjects: 0
Study 31522612 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-NC participants
Number of subjects: 0
Study 28322356 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and caries risk assessment (MICRA programme)
Number of subjects: 214
Study 28322356 — intervention group
Group type: COMPARATOR
Intervention: Routine programme
Number of subjects: 214
Study 27481909 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural exercises
Number of subjects: 0
Study 27481909 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck support pillow
Number of subjects: 0
Study 23506407 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of four dental implants with a fixed prosthesis (experimental arm)
Number of subjects: 45
Study 23506407 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading technique (control arm)
Number of subjects: 45
Study 22832126 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 66 µg/kg/day
Number of subjects: 40
Study 22832126 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 40
Study 19650603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Advantage 123
Number of subjects: 50
Study 19650603 — intervention group
Group type: COMPARATOR
Intervention: Colgate 360 degrees
Number of subjects: 50
Study 17384406 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-focused intervention tools (neighborhood assessment with tip sheets and community resource guide)
Number of subjects: 0
Study 15679573 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training for 15 weeks
Number of subjects: 23
Study 12412826 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomacton 4 mg/ml conventional syringe administration (Treatment A)
Number of subjects: 0
Study 12412826 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomacton 10 mg/ml conventional syringe administration (Treatment B)
Number of subjects: 0
Study 12412826 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomacton 10 mg/ml ZomaJet 2 Vision administration (Treatment C)
Number of subjects: 0
Study 12412826 — intervention group
Group type: COMPARATOR
Intervention: ZomaJet 2 Vision
Number of subjects: 0
Study 12412826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic profiles (IGF-1 and FFA)
Number of subjects: 0
Study 10212734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of emotional, organic and neuropsychological measures (Hospital Anxiety and Depression Scale, Impact of Event Scale, Short Orientation Memory and Concentration Test, Rivermead Post‐Concussion Symptoms Questionnaire, Post‐Traumatic Amnesia) taken at 7‐10 days post-injury
Number of subjects: 57
Study 10212734 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale, Impact of Event Scale, Post‐Traumatic Amnesia
Number of subjects: 57
Study 7597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 20
Study 7597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 20
Study 7597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1.0 mg
Number of subjects: 20
Study 7597114 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2.0 mg
Number of subjects: 20
Study 7597114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1983412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg
Number of subjects: 15
Study 1983412 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20mg
Number of subjects: 15
Study 1983412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150mg
Number of subjects: 15
Study 1983412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6109235 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctaphenine
Number of subjects: 98
Study 6109235 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic Acid (ASA)
Number of subjects: 98
Study 30222484 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-Hz vibration condition
Number of subjects: 18
Study 30222484 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz vibration condition
Number of subjects: 18
Study 30222484 — intervention group
Group type: COMPARATOR
Intervention: Control condition (0-Hz frequency)
Number of subjects: 18
Study 30385451 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger prick autologous blood (FAB) treatment
Number of subjects: 60
Study 26542271 — intervention group
Group type: EXPERIMENTAL
Intervention: PT (Physical Therapy) 3 times/week for 4 weeks
Number of subjects: 41
Study 26542271 — intervention group
Group type: EXPERIMENTAL
Intervention: PT combined with MLD (Manual Lymphatic Drainage) 5 times/week for 4 weeks
Number of subjects: 41